← Back to Patent Explorer
US4692458A Expired / Lapsed US ⏱️ 0.0 years remaining

Anti-hypertensive agents

Assignee: University of Miami
•
Filing: 1980-03-05
•
Granted: 1987-09-08
•
Expires: 2000-03-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel inhibitors of angiotensin converting enzyme having the general formula R--A--S--Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

Inventors

  • 👤 James W. Ryan
  • 👤 Alfred Chung

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 00:31
CPC Classifications
C; C07; C07D; C07D403/00; C07D403/02; C07D403/12; A; A61; A61P; A61P43/00; C07C; C07C327/00; C07D207/00; C07D207/02; C07D207/04; C07D207/10; C07D207/16; C07D207/18; C07D207/22; C07D207/46; C07D207/50; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/60; C07D211/62; C07D211/68; C07D211/72; C07D211/74; C07D211/76; C07D211/80; C07D211/84; C07D211/86; C07D277/00; C07D277/02; C07D277/04; C07D277/06; C07D417/00; C07D417/02; C07D417/12; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06086; C07K5/06139; C07K5/06173; C07K5/08; C07K5/0821; A61K; A61K38/00

Claims Analysis

Total Claims: 79
Claim 1
Independent Claim 901 words
A new compound having the general formula I. R--A--S--Z, and the physiologically acceptable salts thereof, wherein: R is selected from hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonylL-lysyl, pyro-L-glutamyl-L-lysyl, L-arginyl, L-lysyl and pyro-L-glutamyl, A is selected from phenylalanyl, glycyl, alanyl, tryptophyl, tyrosyl, isoleucyl, leucyl, histidyl and valyl and the -amino group of A is in amide linkage with R when R is an acyl group and forms a primary amino group with R when R is hydrogen; S is a sulfur atom joined to A in a thioester linkage; and Z is selected from the following: ##STR60## wherein (i) R 1 and R 1 ' are each hydrogen or halogen, and R 2 and R 3 are each hydrogen, lower alkyl or trifluoromethyl provided that only one of R 2 and R 3 may be trifluoromethyl and further provided that at least one of R 1 , R 1 ', R 2 and R 3 must be halogen or trifluoromethyl; (ii) R 23 is hydrogen or lower alkyl and (iii) m is 0 or 1; ##STR61## wherein (i) R 4 and R 5 are each hydrogen, lower alkyl or phenyl-lower alkylene; (ii) n is 1, 2 or 3; (iii) R 6 is hydrogen or hydroxy or when n is 2, R 6 may also be halogen, and (iv) m and R 23 are as stated in II. above; ##STR62## wherein (i) R 7 is hydrogen, lower alkanoyl or amino (imino)-methyl; (ii) p is 0 or an integer of from 1 to 4; (iii) R 25 is hydrogen but when m is 1, p is 0, R 4 is hydrogen and R 7 is lower alkanoyl, R 25 may also be lower alkyl; (iv) R 8 is selected from hydrogen, lower alkyl and hydroxy lower alkylene when R 9 is selected from hydrogen, lower alkyl, phenyl, phenyl-lower alkylene, hydroxy-lower alkylene, hydroxyphenyl-lower alkylene, amino-lower alkylene, guanidino-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene but R 8 and R 9 may together constitute a (CH 2 ) v bridge wherein v is 3 or 4, thus forming a 5 or 6-membered ring with the N and C to which R 8 and R 9 are respectively attached and in such instance when v is 3 one hydrogen of (CH 2 ) v may be replaced by OH or halogen and when v is 4, one such hydrogen may be replaced by OH; (v) m and R 23 are each as defined in II. above; and (iv) R 4 is as defined in III. above, provided further, however, that m and p may not both be 0. ##STR63## wherein (i) r 10 is hydrogen or lower alkyl; (ii) R 11 is hydrogen, lower alkyl or lower alkanoyl; (iii) X is 0 or S; (iv) m and R 23 are as stated in II. above, and (v) R 8 , R 9 and p are as stated in IV. above; ##STR64## wherein (i) R 12 is selected from carboxy, lower alkoxycarbonyl, carbamoyl, N-substituted carbamoyl and cyano; (ii) m and R 23 are as stated in II. above; and (iii) R 8 , R 9 and p are as stated in IV. above; ##STR65## wherein (i) R 13 is hydrogen, lower alkyl or phenyl-lower alkylene; (ii) R 14 is selected from hydrogen, lower alkyl, phenyl-lower alkylene, hydroxy-lower alkylene, amino-lower alkylene, guanidino-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene; (iii) R 4 and R 5 are as stated in III. above; and (iv) q is 0, 1 or 2 ##STR66## wherein (i) R 15 and R 16 are each hydrogen, lower alkyl, phenyl or phenyl-lower alkylene; (ii) r is 0, 1 or 2; (iii) s is 1, 2, or 3; (iv) R 17 is hydrogen, hydroxy or lower alkyl and when s is 2, R 17 may also be halogen; and (v) R 24 is hydroxy, amino or lower alkoxy; provided that when R 24 is OH, s is 2, and R 17 is H or OH: (a) if r is 0, R 16 may not be methyl or H, and (b) if r is 1, R 15 and R 16 may not both be H and R 16 may not be methyl if R 15 is H ##STR67## wherein (i) R 18 is hydrogen or lower alkyl; (ii) R 19 and R 20 are each lower alkyl and may together constitute a (CH 2 ) w bridge wherein w is 4, to form a ring of 5-carbons with the carbon to which they are each attached; (iii) R 21 is hydrogen or lower alkyl and may constitute with R 19 a (CH 2 ) x bridge wherein x is 3, to form a five-membered ring with the N and C to which they are respectively attached; provided, however, that when R 19 and R 21 constitute (CH 2 ) x , R 18 may not be hydrogen or methyl ##STR68## wherein (i) R 22 is hydrogen or lower alkyl; (ii) t and u are each 0 or 1; (iii) R 23 is as stated in II. above; provided, however, that u may not be zero when R 23 is H; and ##STR69## wherein (i) z is 2 or 3; (ii) R 10 is as stated in V. above, and (iii) R 23 is as stated in II above.
Claim 2
Dependent Claim 901 words
A new compound having the general formula I. R--A--S--Z, and the physiologically acceptable salts thereof, wherein: R is selected from hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonylL-lysyl, pyro-L-glutamyl-L-lysyl, L-arginyl, L-lysyl and pyro-L-glutamyl, A is selected from phenylalanyl, glycyl, alanyl, tryptophyl, tyrosyl, isoleucyl, leucyl, histidyl and valyl and the -amino group of A is in amide linkage with R when R is an acyl group and forms a primary amino group with R when R is hydrogen; S is a sulfur atom joined to A in a thioester linkage; and Z is selected from the following: ##STR60## wherein (i) R 1 and R 1 ' are each hydrogen or halogen, and R 2 and R 3 are each hydrogen, lower alkyl or trifluoromethyl provided that only one of R 2 and R 3 may be trifluoromethyl and further provided that at least one of R 1 , R 1 ', R 2 and R 3 must be halogen or trifluoromethyl; (ii) R 23 is hydrogen or lower alkyl and (iii) m is 0 or 1; ##STR61## wherein (i) R 4 and R 5 are each hydrogen, lower alkyl or phenyl-lower alkylene; (ii) n is 1, 2 or 3; (iii) R 6 is hydrogen or hydroxy or when n is 2, R 6 may also be halogen, and (iv) m and R 23 are as stated in II. above; ##STR62## wherein (i) R 7 is hydrogen, lower alkanoyl or amino (imino)-methyl; (ii) p is 0 or an integer of from 1 to 4; (iii) R 25 is hydrogen but when m is 1, p is 0, R 4 is hydrogen and R 7 is lower alkanoyl, R 25 may also be lower alkyl; (iv) R 8 is selected from hydrogen, lower alkyl and hydroxy lower alkylene when R 9 is selected from hydrogen, lower alkyl, phenyl, phenyl-lower alkylene, hydroxy-lower alkylene, hydroxyphenyl-lower alkylene, amino-lower alkylene, guanidino-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene but R 8 and R 9 may together constitute a (CH 2 ) v bridge wherein v is 3 or 4, thus forming a 5 or 6-membered ring with the N and C to which R 8 and R 9 are respectively attached and in such instance when v is 3 one hydrogen of (CH 2 ) v may be replaced by OH or halogen and when v is 4, one such hydrogen may be replaced by OH; (v) m and R 23 are each as defined in II. above; and (iv) R 4 is as defined in III. above, provided further, however, that m and p may not both be 0. ##STR63## wherein (i) r 10 is hydrogen or lower alkyl; (ii) R 11 is hydrogen, lower alkyl or lower alkanoyl; (iii) X is 0 or S; (iv) m and R 23 are as stated in II. above, and (v) R 8 , R 9 and p are as stated in IV. above; ##STR64## wherein (i) R 12 is selected from carboxy, lower alkoxycarbonyl, carbamoyl, N-substituted carbamoyl and cyano; (ii) m and R 23 are as stated in II. above; and (iii) R 8 , R 9 and p are as stated in IV. above; ##STR65## wherein (i) R 13 is hydrogen, lower alkyl or phenyl-lower alkylene; (ii) R 14 is selected from hydrogen, lower alkyl, phenyl-lower alkylene, hydroxy-lower alkylene, amino-lower alkylene, guanidino-lower alkylene, imidazolyl-lower alkylene, indolyl-lower alkylene, mercapto-lower alkylene, lower alkyl-thio-lower alkylene, carbamoyl-lower alkylene and carboxy-lower alkylene; (iii) R 4 and R 5 are as stated in III. above; and (iv) q is 0, 1 or 2 ##STR66## wherein (i) R 15 and R 16 are each hydrogen, lower alkyl, phenyl or phenyl-lower alkylene; (ii) r is 0, 1 or 2; (iii) s is 1, 2, or 3; (iv) R 17 is hydrogen, hydroxy or lower alkyl and when s is 2, R 17 may also be halogen; and (v) R 24 is hydroxy, amino or lower alkoxy; provided that when R 24 is OH, s is 2, and R 17 is H or OH: (a) if r is 0, R 16 may not be methyl or H, and (b) if r is 1, R 15 and R 16 may not both be H and R 16 may not be methyl if R 15 is H ##STR67## wherein (i) R 18 is hydrogen or lower alkyl; (ii) R 19 and R 20 are each lower alkyl and may together constitute a (CH 2 ) w bridge wherein w is 4, to form a ring of 5-carbons with the carbon to which they are each attached; (iii) R 21 is hydrogen or lower alkyl and may constitute with R 19 a (CH 2 ) x bridge wherein x is 3, to form a five-membered ring with the N and C to which they are respectively attached; provided, however, that when R 19 and R 21 constitute (CH 2 ) x , R 18 may not be hydrogen or methyl ##STR68## wherein (i) R 22 is hydrogen or lower alkyl; (ii) t and u are each 0 or 1; (iii) R 23 is as stated in II. above; provided, however, that u may not be zero when R 23 is H; and ##STR69## wherein (i) z is 2 or 3; (ii) R 10 is as stated in V. above, and (iii) R 23 is as stated in II above.
Claim 3
Dependent Claim 12 words
The compound of claim 1 wherein A is glycyl, phenylalanyl or tryptophyl.
Claim 4
Dependent Claim 16 words
The compound of claim 1 wherein R is hydrogen, acetyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl or pyro-L-glutamyl.
Claim 5
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula II.
Claim 6
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula III.
Claim 7
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula IV.
Claim 8
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula V.
Claim 9
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula VI.
Claim 10
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula VII.
Claim 11
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula VIII.
Claim 12
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula IX.
Claim 13
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula X.
Claim 14
Dependent Claim 12 words
The compound of claim 1 wherein Z is defined by formula XI.
Claim 15
Dependent Claim 9 words
The compound of claim 5 wherein n is 2.
Claim 16
Dependent Claim 53 words
The compound of claim 6, 7 or 8 wherein R 8 and R 9 together form a --CH 2 CH 2 CH 2 -- bridge which completes a ring of 5 atoms with the nitrogen and carbon to which they are attached, one carbon optionally bearing a hydroxy group or a halogen group.
Claim 17
Dependent Claim 9 words
The compound of claim 10 wherein s is 2.
Claim 18
Dependent Claim 39 words
The compound of claim 11 wherein R 19 and R 21 together form a --CH 2 CH 2 CH 2 -- bridge which completes a ring of 5 atoms with the nitrogen and carbon to which they are attached.
Claim 19
Dependent Claim 9 words
The compound of claim 12 wherein u is 0.
Claim 20
Dependent Claim 9 words
The compound of claim 13 wherein z is 2.
Claim 21
Dependent Claim 16 words
The compound of claim 1, 4 or 9 wherein R is benzoyl and A is phenylalanyl.
Claim 22
Dependent Claim 15 words
The compound of claim 5 or 14 wherein R is benzoyl and A is phenylalanyl.
Claim 23
Dependent Claim 17 words
The compound of claim 6, 7, 8 or 15 wherein R is benzoyl and A is phenylalanyl.
Claim 24
Dependent Claim 15 words
The compound of claim 10 or 16 wherein R is benzoyl and A is phenylalanyl.
Claim 25
Dependent Claim 15 words
The compound of claim 11 or 17 wherein R is benzoyl and A is phenylalanyl.
Claim 26
Dependent Claim 15 words
The compound of claim 12 or 18 wherein R is benzoyl and A is phenylalanyl.
Claim 27
Dependent Claim 15 words
The compound of claim 13 or 19 wherein R is benzoyl and A is phenylalanyl.
Claim 28
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 1.
Claim 29
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 2.
Claim 30
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 3.
Claim 31
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 4.
Claim 32
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 5.
Claim 33
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 6.
Claim 34
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 7.
Claim 35
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 8.
Claim 36
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 9.
Claim 37
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 10.
Claim 38
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 11.
Claim 39
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 12.
Claim 40
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 13.
Claim 41
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 14.
Claim 42
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 15.
Claim 43
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 16.
Claim 44
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 17.
Claim 45
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 18.
Claim 46
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 19.
Claim 47
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 20.
Claim 48
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 21.
Claim 49
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 22.
Claim 50
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 23.
Claim 51
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 24.
Claim 52
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 25.
Claim 53
Dependent Claim 29 words
A method for inhibiting angiotensin converting enzyme in vivo which comprises administering to a mammal in need of such treatment an effective dose of the compound of claim 26.
Claim 54
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 1.
Claim 55
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 2.
Claim 56
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 3.
Claim 57
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 4.
Claim 58
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 5.
Claim 59
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 6.
Claim 60
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 7.
Claim 61
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 8.
Claim 62
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 9.
Claim 63
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 10.
Claim 64
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 11.
Claim 65
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 12.
Claim 66
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 13.
Claim 67
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 14.
Claim 68
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 15.
Claim 69
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 16.
Claim 70
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 17.
Claim 71
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 18.
Claim 72
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 19.
Claim 73
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 20.
Claim 74
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 21.
Claim 75
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 22.
Claim 76
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 23.
Claim 77
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 24.
Claim 78
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 25.
Claim 79
Dependent Claim 28 words
A method for reducing in vivo the blood pressure of a mammal in the hypertensive state which comprises administering an effective dose of the compound of claim 26.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-09-07 1991-03-09 1991-09-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-09-07 1995-03-09 1995-09-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-09-07 1999-03-09 1999-09-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag